new glp-1 drugs in development What's next for innovation: A primer on the race reshaping pharma and chronic disease care GLP-1 Drugs: 6 Things We've
Description
CagriSema combines semaglutide with cagrilintide, an amylin analogue
Targets 6 , 181189 (2005)
Food and Drug Administration , 2025
Often, medications have off-label uses, which means they are taken for other conditions not officially approved by the FDA
The injectable versus oral comparison helps clarify the tradeoffs between convenience and potency for various peptide therapies
Vomiting, diarrhea and constipation occur less frequently but still affect notable numbers of patients
